Nomura Holdings Inc Biomarin Pharmaceutical Inc Call Options Transaction History

Nomura Holdings Inc

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$69.02 - $93.84 $2.05 Million - $2.79 Million	29,700 Added 13.39%	251,500 $17.7 Million
Q2 2024 Aug 14, 2024	BUY	$74.43 - $92.22 $5.64 Million - $6.99 Million	75,800 Added 51.92%	221,800 $18.3 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $12.2 Million - $14.5 Million	146,000 New	146,000 $12.8 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $12.9 Million - $16.7 Million	-169,900 Reduced 83.33%	34,000 $3.28 Million
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $17.3 Million - $19.3 Million	203,900 New	203,900 $18 Million
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $5.85 Million - $7.82 Million	66,700 New	66,700 $6.49 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $13.2 Million - $16 Million	-184,000 Reduced 83.64%	36,000 $3.06 Million
Q1 2020 May 14, 2020	BUY	$71.37 - $96.85 $15 Million - $20.3 Million	210,000 Added 2100.0%	220,000 $18.6 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $3.52 Million - $4.11 Million	-43,800 Reduced 81.41%	10,000 $0
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $4.09 Million - $5.33 Million	53,800 New	53,800 $0

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.